상처치료 시장조사

---

집에서 응급처치로 경미한 상처나 부상을 치료할 수 있습니다. 일부는 다른 것보다 크거나 깊습니다. 또한, 이러한 상처는 치료하고 감염을 예방하는 데 도움을 주는 의료 전문가가 필요합니다. 상처치료센터는 낫지 않는 상처를 치료하는 또 하나의 의료시설이다. 2주가 지났는데 낫는 기미가 보이지 않는 부상이 있습니까? 그렇다면 상처치료시설에 가보시면 도움이 될 것 같습니다. 완전히 치유되지 않은 6주 된 상처는 만성적입니다. 이러한 상처는 상처 치료 시설에서 추가 관리가 필요합니다.

상처 관리가 왜 중요한가요?

사람들이 상처나 염증을 관리하지 않으면 건강에 심각한 문제가 될 수 있습니다. 상처는 급성 또는 만성으로 알려져 있습니다. 만성 상처는 4~6주 후에도 낫는 기미가 보이지 않습니다. 상처가 치유되지 않으면 감염, 통증, 장애, 심지어 절단으로 이어질 수 있습니다. 상처관리의 중요성을 간과할 수는 없습니다. 만성 상처를 치료하지 않으면 감염될 가능성이 높습니다.

Wound Care Market Research: How Leading Manufacturers Win Clinician Preference

Wound care is a clinician-led category. The nurse at the bedside, not the procurement contract, decides which dressing comes off the cart. Manufacturers who understand this win share. Those who optimize for hospital formulary alone leave growth on the table.

The category rewards specificity. Antimicrobial dressings, negative pressure wound therapy, collagen matrices, and skin substitutes each follow different adoption logics. Wound care market research that treats them as one segment produces generic insight. Research that isolates the decision maker, the wound type, and the care setting produces commercial advantage.

Why Wound Care Market Research Rewards Clinician-Level Depth

The prescriber in wound care is rarely the physician of record. Wound ostomy continence nurses (WOCNs), wound care directors, and nurse practitioners drive product selection in long-term care, home health, and hospital outpatient departments. They build treatment outlines based on exudate level, bioburden, periwound condition, and healing trajectory. They escalate to silver, iodine, or PHMB antimicrobials when stalled wounds show biofilm signatures.

SIS International’s structured expert interviews with wound care nurses and WOCNs across U.S. acute and post-acute settings indicate that antimicrobial dressing selection is governed less by brand preference than by a two-week trial-and-escalate protocol tied to wound bed appearance. Manufacturers who map their value story to that escalation logic enter the consideration set. Those who lead with mechanism-of-action claims disconnected from the clinician’s decision sequence get filtered out before sampling.

This is why surveys alone underperform in wound care. The decision is tactile and visual. Clinicians evaluate conformability, exudate handling, atraumatic removal, and wear time at the dressing change. Concept tests without product-in-hand evaluation miss the variables that actually drive switching.

The Four Decision Axes That Shape Wound Care Adoption

Effective wound care market research isolates four axes that determine commercial uptake. Each carries different evidence requirements and different KOL mapping needs.

Source: SIS International Research

Manufacturers often build a single launch narrative across all four. The narrative collapses on contact with the value analysis committee, which speaks the language of cost per healed wound, not clinical novelty. It also collapses with the home health agency, which optimizes for nurse visits per episode under PDGM reimbursement.

What Patient Journey Mapping Reveals in Chronic Wound Categories

Diabetic foot ulcers, venous leg ulcers, and pressure injuries each follow distinct referral and reimbursement pathways. A diabetic foot ulcer patient may pass through primary care, podiatry, vascular surgery, and a wound center within a single episode. Each handoff is a product decision point. Each clinician operates under different incentives.

Patient journey mapping in wound care identifies where products enter, exit, and get switched. It also surfaces the abandonment points. Across SIS International’s qualitative work with U.S. wound care clinicians, a recurring pattern emerges: products selected in the wound center are frequently substituted within seven to fourteen days of home health transition because the home agency stocks a different formulary. Manufacturers who fail to model the cross-setting handoff lose volume they assumed they had won.

This is where real-world evidence and claims-linked analysis complement primary qualitative work. The clinician interview reveals the why. The claims data reveals the where and how often. Together they shape a payer value story that addresses cost per healed wound across the full episode rather than the single dressing change.

How Leading Manufacturers Build Launch Sequencing for Advanced Modalities

Skin substitutes, cellular and tissue-based products, and negative pressure wound therapy operate under reimbursement structures that change adoption math entirely. CMS coverage decisions, the LCD for cellular and tissue products, and the transition of skin substitutes to ASP-based reimbursement reshape which products get used and where. Indication prioritization matters here. A product cleared for diabetic foot ulcers and venous leg ulcers may see ninety percent of its volume in one indication based on reimbursement and KOL endorsement, not clinical breadth.

Launch sequencing should follow the reimbursement gradient. Hospital outpatient departments and wound centers with established billing infrastructure absorb advanced modalities first. Physician offices follow. Home health is last because payment models lag. Manufacturers who launch broadly and uniformly burn commercial spend on accounts that cannot yet bill the product profitably.

The SIS Approach to Wound Care Market Research

SIS International conducts wound care market research through B2B expert interviews with WOCNs, wound care directors, vascular surgeons, podiatrists, and home health clinical leaders, paired with concept and product evaluation sessions that put the dressing in the clinician’s hands. This combination surfaces the prescription behavior, the escalation triggers, and the tactile evaluation that drive switching. It also tests the payer value story against the value analysis committee logic before launch.

SIS International’s proprietary research in antimicrobial wound care indicates that clinicians evaluate new dressings against a mental benchmark of their current go-to product, and that benchmark shifts only when the new product demonstrates a clear advantage on either wear time, exudate handling, or atraumatic removal. Generic superiority claims do not move the benchmark. Specific, clinician-relevant proof points do.

The firms that grow share in wound care invest in clinician-level intelligence before committing to launch sequencing, KOL mapping, and formulary positioning. Wound care market research conducted at that depth turns a crowded category into a defensible position.

SIS 인터내셔널 소개

SIS 국제 정량적, 정성적, 전략 연구를 제공합니다. 우리는 의사결정을 위한 데이터, 도구, 전략, 보고서 및 통찰력을 제공합니다. 또한 인터뷰, 설문 조사, 포커스 그룹, 기타 시장 조사 방법 및 접근 방식을 수행합니다. 문의하기 다음 시장 조사 프로젝트를 위해.